SAN
JOSE, Calif., June 28,
2024 /PRNewswire/ -- BridGene Biosciences, Inc., a
leader in developing covalent small molecule drugs for
traditional "hard-to-drug" targets, announced today that the first
patient has been dosed in its Phase 1 clinical trial of BGC515, a
novel TEAD inhibitor discovered through BridGene's
cutting-edge chemoproteomic platform, IMTAC™. This milestone
highlights the potential of BridGene's innovative chemoproteomics
approach.
The Phase 1 study will enroll subjects in both the US
and China (NCT06452160) to
evaluate the safety, tolerability, pharmacokinetics,
pharmacodynamics, and preliminary antitumor activity of
BGC515 as a single agent in patients with advanced solid
tumors, including malignant mesothelioma, epithelioid
hemangioendothelioma, and other solid tumors with hippo pathway
dysregulation. Dr. Timothy Yap,
Ph.D., FRCP, Professor in the Department of Investigational Cancer
Therapeutics (Phase I Program) and Head of Clinical Development,
Therapeutics Discovery Division at the University of Texas MD Anderson Cancer Center, is
the principal investigator at the initial US site, where the first
patient has been enrolled.
"We are delighted to begin the clinical evaluation of BGC515
with the dosing of our first patient, and we look forward to the
evaluation of the initial safety and efficacy of this exciting
compound," said Jeremy Barton, M.D.,
Chief Medical Officer of BridGene Biosciences.
"The initiation and dosing of our first drug in clinical
development from our chemoproteomic platform marks a major
inflection point for BridGene," stated Ping
Cao, Ph.D., Co-Founder and CEO of BridGene Biosciences.
"This achievement underscores our commitment to addressing unmet
medical needs through innovative therapeutic solutions. BGC515
represents a breakthrough in targeting the TEAD proteins, a
critical component in the Hippo signaling pathway. We are proud of
the progress we have made in a short time, developing a pipeline
that includes previously undruggable targets for prominent oncology
and immunology diseases."
BridGene Biosciences is advancing multiple novel drug discovery
programs toward the clinic and has over a dozen similar
opportunities emerging in early discovery.
About the Hippo Pathway and BGC515
The Hippo pathway
is a key pathway used by cells to control expression of a group of
genes by regulating activity of transcription factors YAP and TAZ.
YAP and TAZ function in a complex with partner proteins, the TEADs,
which are the targets of BGC515. A variety of human cancers depend
on activation of YAP and TAZ, which can occur by various
mechanisms.
BGC515 is an internally-developed, orally-administered,
covalent TEAD inhibitor.
About BridGene Biosciences
BridGene is a biotechnology
company focused on discovering and developing innovative small
molecules that drug traditionally undruggable targets, providing
new paths to treat diseases. By using its proprietary
chemoproteomic platform, IMTAC™, BridGene is able to screen small
molecules against all proteins in live cells to discover drug
candidates for high value and previously undruggable targets. For
this purpose, BridGene takes advantage of its proprietary, diverse
covalent library of tagged, drug-like small molecules. The ultimate
goal is to enable breakthrough small-molecule drug discovery and to
expand the mechanisms to treat diseases, with targets previously
inaccessible to small molecules. BridGene is advancing a
diversified pipeline of first-in-class drugs for targets in
multiple disease areas. For more information, visit
https://bridgenebio.com/.
Contact
Tiberend Strategic Advisors, Inc.
Daniel Kontoh-Boateng
(investors)
862-213-1398
dboateng@tiberend.com
Dave Schemelia (media)
dschemelia@tiberend.com
609-468-9325
View original content to download
multimedia:https://www.prnewswire.com/news-releases/bridgene-biosciences-announces-dosing-of-first-patient-in-phase-1-study-evaluating-novel-tead-inhibitor-bgc515-in-advanced-solid-tumors-302185160.html
SOURCE BridGene Biosciences